Chiesi Farmaceutici S.p.A.

• A study to find an efficacious and safe dose of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis Pending
  2024-514246-37-00 Phase II 11 countries ZAMPILIMAB
• A 52 week study in which neither Sponsor or participant know the treatment assigned to subjects to compare the experimental drug (CHF 5993) … Pending
  2024-514248-95-00 Phase III 3 countries FLUTICASONE PROPIONATE, SALMETEROL; GLYCOPYRRONIUM BROMIDE, FORMOTEROL FUMARATE …
• Cangrelor safety and pharmacodynamics in paediatric subjects with congenital heart disease Pending
  2025-523109-14-00 Phase III 4 countries CANGRELOR TETRASODIUM
• BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/… Pending
  2025-524289-56-00 Phase IV 8 countries BECLOMETASONE DIPROPIONATE, GLYCOPYRRONIUM BROMIDE, FORMOTEROL FUMARATE DIHYDRAT…
• Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting
  2025-521456-35-00 Phase II 8 countries BECLOMETASONE DIPROPIONATE; BECLOMETASONE DIPROPIONATE, GLYCOPYRRONIUM BROMIDE, …
• Evaluation of safety, side effects and how the drug CHF6467 administrated via intranasal route is absorbed, modified and removed in healthy … Recruiting
  2025-521455-23-00 Phase I (Other) 1 country
• A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents with Fabry Disease Recruiting
  2022-503128-29-00 Phase II/III 4 countries PEGUNIGALSIDASE ALFA
• A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily… Recruiting
  2022-502950-14-00 Phase IV 3 countries METRELEPTIN
• A clinical Study to Evaluate Metreleptin Treatment in Subjects with Partial Lipodystrophy over 12-Month Timeframe Ended
  2022-501799-24-00 Phase III 4 countries METRELEPTIN
• Cardiovascular safety assessment of Tanimilast in healthy volunteers Ended
  2024-516861-35-00 Phase I (Other) 1 country
• A comparison study between adolescents with asthma and adults with asthma on how they absorb, metabolise and eliminate CHF 6001 Ended
  2024-516483-29-00 Phase II 1 country TANIMILAST
• Open-label, non-randomised, single-dose, one sequence, two-period, cross-over study to investigate the effect of inhibition of P-glycoprotei… Ended
  2024-516475-32-00 Phase I (Other) 1 country
• Not applicable Ended
  2024-518150-17-00 Phase I (Other) 1 country
• Evaluation of safety, side effects and how the inhaled drug CHF10073 is absorbed, modified and removed from the body when administered alone… Ended
  2024-515442-17-00 Phase I 1 country
• Evaluation of the CHF 5993 concentration in blood, after inhalation with two different devices, (NEXThaler® versus pMDI), with and without A… Ended
  2024-512792-13-00 Phase I (Other) 1 country
• Comparison of the study drug CHF 1535 formulated with two different propellants to learn about drug levels in blood and safety after inhalat… Ended
  2024-514247-28-00 Phase I (Other) 1 country
• Comparison of the study drug CHF 1535 formulated with two different propellants to learn about drug levels in blood and safety after inhalat… Ended
  2023-510171-59-00 Phase I (Other) 1 country
• Effect of Erythromycin on the absorption, metabolism and elimination of CHF6001 in healthy volunteers Ended
  2023-507300-30-00 Phase I (Other) 1 country
• Evaluation of the effect of CHF6795 on the pharmacokinetics of midazolam, repaglinide and rosuvastatin in healthy subjects Ended
  2023-507997-41-00 Phase I (Other) 1 country
• A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 p… Ended
  2023-503333-22-00 Phase III 11 countries GLYCOPYRRONIUM BROMIDE, FORMOTEROL FUMARATE DIHYDRATE, BECLOMETASONE DIPROPIONAT…
• Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy Ended
  2022-502208-64-00 Phase II 10 countries TANIMILAST
• A phase I study to evaluate an investigational medicinal product for the treatment of asthma, in healthy adult participants. Ended
  2023-504326-19-00 Phase I (Other) 1 country BECLOMETASONE DIPROPIONATE; BECLOMETASONE DIPROPIONATE ANHYDROUS
• A study comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF5993 With the Fixed Dose Dual Combination CHF153… Ended
  2023-510172-31-00 Phase III 5 countries FORMOTEROL FUMARATE DIHYDRATE, BECLOMETASONE DIPROPIONATE ANHYDROUS; GLYCOPYRRON…
• The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy Ended
  2023-510174-13-00 Phase III 14 countries ROFLUMILAST; TANIMILAST

Showing 1–24 of 26 trials